AZD-1940 explained

AZD-1940 is a drug developed by AstraZeneca, that is a peripherally selective cannabinoid agonist which binds with high affinity to both the CB₁ and CB₂ receptors. It was developed for the treatment of neuropathic pain, but while it showed good peripheral selectivity in animal studies,^[1] in human clinical trials it failed to show sufficient analgesic efficacy and produced unexpectedly strong side effects associated with central cannabinoid activity, and so was discontinued from further development.^{[2] [3]}

See also

• A-PONASA
• AZ-11713908
• 2F-QMPSB
• RQ-00202730

References

1. Schou M, Varnäs K, Jucaite A, Gulyás B, Halldin C, Farde L . Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate . Nuclear Medicine and Biology . 40 . 3 . 410–4 . April 2013 . 23352602 . 10.1016/j.nucmedbio.2012.10.011 .
2. Kalliomäki J, Segerdahl M, Webster L, Reimfelt A, Huizar K, Annas P, Karlsten R, Quiding H . 6 . Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal . Scandinavian Journal of Pain . 4 . 1 . 17–22 . January 2013 . 29913883 . 10.1016/j.sjpain.2012.08.004 . 49302159 .
3. Kalliomäki J, Annas P, Huizar K, Clarke C, Zettergren A, Karlsten R, Segerdahl M . Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia . Clinical and Experimental Pharmacology & Physiology . 40 . 3 . 212–8 . March 2013 . 23324098 . 10.1111/1440-1681.12051 . 1630384 .